I know it has been said before, but for me this sentence screams confidence of a positive December result...
"In order to accelerate the overall development plan, in parallel with conducting the Phase 2 trials Neuren is executing the additional development work required to be ready for Phase 3 development. This includes non-clinical toxicity studies to support longer clinical trials and commercial use of the product as well as optimisation of the drug product and drug substance manufacturing arrangements."
How confident? They are even spending hard-earned money on getting ready for PhIII !!!
"In operating cash outflows, R&D payments of A$6.2 million mainly related to the NNZ-2591 Phase 2 clinical trials and the foundational work to prepare for Phase 3 development of NNZ-2591 across multiple indications."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)